Rubicon Research Limited has announced its initial public offering (IPO), providing investors an opportunity to participate in one of India’s prominent pharmaceutical research companies. The IPO is a book-built issue aggregating ₹1,377.50 crore, comprising a fresh issue of 1.03 crore shares worth ₹500 crore and an offer for sale of 1.81 crore shares worth ₹877.50 crore. This combination allows the company to raise capital for business expansion while enabling existing shareholders to sell a portion of their holdings.

Key Details of Rubicon Research IPO

The subscription window for the Rubicon Research IPO opens on October 9, 2025, and will close on October 13, 2025. Investors must apply within this period to be eligible for allotment of shares, which is expected to be finalized on October 14, 2025. The IPO will be listed on BSE and NSE, with a tentative listing date fixed as October 16, 2025.

The price band for the IPO has been set at ₹461 to ₹485 per share, making it accessible to both retail and institutional investors. The lot size for retail investors is 30 shares, amounting to a minimum investment of ₹14,550 at the upper price band. For non-institutional investors, the lot size is 14 lots (420 shares), and for qualified institutional buyers, it is 69 lots (2,070 shares), allowing participation based on investment capacity.

Investment Opportunity and IPO Structure

The fresh issue component of ₹500 crore will be used by the company to fund research, development, and expansion projects, strengthening Rubicon Research’s position in the pharmaceutical sector. The offer for sale (OFS) component of ₹877.50 crore enables existing shareholders to monetize part of their holdings while allowing new investors to participate in the company’s growth story.

Investors get an opportunity to hold equity in a research-driven pharmaceutical company, known for its focus on contract research, formulation development, and manufacturing services. The IPO presents a way to diversify portfolios into a sector with high growth potential, especially in India’s rapidly expanding healthcare and pharmaceutical industry.

Allotment and Listing

The allotment process, expected on October 14, 2025, will determine the number of shares allocated to investors across retail, non-institutional, and institutional categories. Once allotted, the shares will list on BSE and NSE on October 16, 2025, allowing investors to trade in the secondary market.

The listing process ensures liquidity for investors, and the market will establish a benchmark price reflecting demand and investor sentiment for Rubicon Research shares. The IPO’s performance on listing day will be closely watched by market analysts, investors, and the pharmaceutical industry.

Strategic Importance of the IPO

The Rubicon Research IPO is significant for multiple reasons. The fresh capital raised will be deployed for research and development, technology upgradation, and business expansion, which can drive long-term revenue growth. The IPO also enhances corporate governance and market visibility, as a listed company must adhere to stringent disclosure norms under SEBI regulations.

For investors, the IPO provides a chance to invest in a stable and research-focused company, with potential for capital appreciation and long-term returns. The combination of fresh issue and OFS provides flexibility and an opportunity for both the company and shareholders.

Conclusion

The Rubicon Research IPO offers an attractive opportunity for investors seeking exposure to the pharmaceutical and research sector in India. With a subscription period from October 9 to October 13, 2025, a total issue size of ₹1,377.50 crore, and allotment on October 14, 2025, investors have clear timelines to participate.

Listing on BSE and NSE on October 16, 2025 ensures liquidity and a transparent market price. The IPO allows investors to hold equity in a research-driven pharmaceutical company, supporting its growth initiatives while participating in India’s booming healthcare and pharmaceutical sector.

This IPO is expected to attract attention from retail, non-institutional, and institutional investors, reflecting confidence in the company’s research capabilities and future growth prospects.

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.